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Abstract
Background: Visceral leishmaniasis (VL) is a severe disease caused by Leishmania infantum in the Mediterranean
basin, and is associated with considerable morbidity and mortality. Infantile VL may begin suddenly, with high fever
and vomiting, or insidiously, with irregular daily fever, anorexia, and marked splenomegaly. Delays in diagnosis of VL
are common, highlighting the need for increased awareness of clinicians for VL in endemic European countries.
Case presentation: We report 4 cases of young children in northern Italy presenting with persistent fever of
unknown origin and diagnosed with VL by serological and molecular methods. At the time of diagnosis, these
patients showed an unusual echographic pattern characterized by multiple iso-hypoechoic nodules associated with
splenomegaly.
Conclusion: We suggest that detection of spleen nodules represents a signature of VL in infants, thus helping to
diagnose systemic Leishmania infantum infection in children.
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Background
Visceral leishmaniasis (VL), or kala-azar, is a severe
disease caused by various Leishmania species belonging
to the Leishmania donovani complex and is associated
with considerable morbidity and mortality [1]. In VL,
parasites spread systemically to propagate in the macro-
phages of internal organs such as the liver, spleen, bone
marrow, and lymph nodes. VL is observed in immuno-
competent hosts in endemic areas, but it occasionally
occurs as complication of immunodeficiency and auto-
immune diseases.
The Mediterranean type of VL is usually caused by
Leishmania infantum [2]. Dogs are the main reservoirs
of this parasite that frequently infects infants and young
children up to 4 years of age [1]. Since the 1990s, human
VL has been on the increase in Italy, with new foci de-
tected not only within endemic areas, but also in north-
ern regions previously regarded as non-endemic [3]. In
2013, a dramatic increase of VL cases has been reported
in Bologna Province, which is located in north-eastern
Italy [4]. During this outbreak, 5 pediatric cases were
also described.
Infantile VL may begin suddenly, with high fever and
vomiting, or insidiously, with irregular daily fever, an-
orexia, weight loss, and pallor. Splenomegaly develops
gradually and may become marked; it is evident by the
end of the first month of symptom initiation [5].
Here, we report 4 cases of young children presenting
with persistent fever of unknown origin (FUO) diagnosed
as VL in Bologna Province, Italy. These patients had sple-
nomegaly and an echographic pattern characterized by
widespread echostructural alteration of the spleen and
the presence of multiple iso-hypoechoic nodules, mostly
smaller than 1 cm. Such a pattern has been previously
reported only occasionally in association with VL.
Case presentation
Four children were admitted to the St. Orsola-Malpighi
University Hospital (Bologna, Italy) from March to April
2013 because of persistent fever. All patients resided in
Bologna Province. In all cases, VL began with unex-
plained fever, weight loss, and mild-to-moderate anemia.* Correspondence: fraia.melchionda@aosp.bo.it
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Patient 1
A 5 month-old girl was admitted to a secondary hospital
with a 2-week history of weight loss and fever unrespon-
sive to antibiotic therapy. She was born at term after a
physiological pregnancy, and gained weight normally
after birth. During this first admission, serological tests
for human immunodeficiency virus (HIV), Epstein-Barr
virus (EBV), hepatitis A, B, and C viruses, cytomegalo-
virus (CMV), parvovirus B19, salmonella, and brucella
yielded negative results. Aerobic and anaerobic blood
cultures, tuberculin sensitivity test, thoracic radiography,
and abdominal ultrasonography showed no specific cause
for the fever. The patient was transferred to St. Orsola-
Malpighi University Hospital for evaluation after 4 weeks
of fever and the appearance of moderate three-lineage
cytopenias. Serological studies for human herpesvirus-6
(HHV6), measles, adenovirus, Borrelia spp., and Toxo-
plasma gondii yielded negative results. Microscopic
examination of the bone marrow aspirate showed hemo-
phagocytosis features and absence of Leishmania amas-
tigotes. Abdominal ultrasonography revealed a markedly
enlarged spleen with diffuse multifocal hypoechoic nod-
ules (Figure 1, Pt 1).
Serum abnormalities included elevated ferritin level
(13362 ng/mL) indicating severe inflammation, increased
soluble interleukin-2 receptor (sIL2R; >7500 UI/mL),
hypertriglyceridemia (674 mg/dL), hypofibrinogenemia
(100 mg/dl), severe hypoalbuminemia, anemia (hemoglobin
[Hb], 8 g/dL), neutropenia (WBC count, 1650/μL), and
thrombocytopenia (platelets [PLT], 100000/μL). Differen-
tial diagnosis included familial hemophagocytic lympho-
histiocytosis (HLH) syndrome, as 6 of the 8 diagnostic
criteria for HLH proposed by the HLH04 study [6] were
present in this patient. HLH therapy was initiated, in-
cluding dexamethasone, cyclosporine, and etoposide,
because of the patient’s worsening clinical condition
even though no genetic mutations related to familial HLH
were present. Serological assays were performed to detect
anti-Leishmania antibodies; a serum sample of the patient
tested positive for anti-Leishmania IgG by a rk39-based
immunochromatographic test (RapydTest, DID, Italy) [7],
and the positivity was confirmed by an indirect immuno-
fluorescence assay (IFAT) performed by the Public Health
National reference center (titer: 1:80). A genus-specific
real-time PCR for Leishmania spp. [8] was then per-
formed on bone marrow aspirate and showed the pres-
ence of protozoan DNA, confirming the diagnosis of VL
[9]. HLH04 therapy was discontinued, and VL treat-
ment consisting of high-dose liposomal amphotericin B
(LAMB) (10 mg/kg IV for 1 day) was carried out. The
onset of VL infection was atypical, but consistent with
the Leishmania transmission period and immaturity of
the immune system of this patient. A gradual reduction
in ferritin and sIL2R levels occurred after 10–15 days
Figure 1 Spleen sonography of 4 patients showing splenomegaly with multiple small iso-hypoechoic nodules (arrows).
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of therapy, and after 1 month, anemia and splenomeg-
aly resolved with reduction of nodules.
Patient 2
A 1-year-old girl was referred to the St. Orsola-Malpighi
University Hospital with a 3-week history of fever and
otitis while traveling in Morocco. Laboratory tests showed
hyperferritinemia (2330 ng/mL), increased transaminases
(aspartate aminotransferase [AST], 172 U/L; alanine
aminotransferase [ALT], 185 U/L), hypertriglyceridemia
(299 mg/dL), elevated sIL2R (1899 UI/mL), and spleno-
megaly with multiple iso-hypoechoic nodules (Figure 1,
Pt 2). Familial HLH syndrome was considered in the
differential diagnosis, but the patient received only 3 of
8 points on HLH scoring. No bacterial or fungal growth
was detected by blood culture, and serum samples tested
negative for antibodies against herpesviruses, hepatitis
viruses, parvovirus B19, adenovirus, HIV, Borrelia, and
Toxoplasma. Microscopic examination of bone marrow
showed no Leishmania amastigotes. However, the bone
marrow sample tested positive for Leishmania spp. and
for Leishmania infantum DNA, respectively by employ-
ing a genus-specific [8], and a species-specific real-time
PCR [10]. Finally, anti-Leishmania antibodies were
found in serum by RapydTest and IFAT (titer: 1:160),
consistent with a diagnosis of VL. Treatment for VL was
carried out with LAMB (10 mg/kg IV), and the fever dis-
appeared after 48 hours; after 2 weeks, decreased levels of
inflammatory markers were observed. In addition, reduced
splenomegaly and nodules were observed, with complete
resolution reached after 1 month and after 4 months,
respectively.
Patient 3
An 18-month-old girl was referred to the St. Orsola-
Malpighi University Hospital after 7 days of fever unre-
sponsive to antibiotic therapy. Blood tests showed anemia
(Hb, 7.9 g/dl), severe hypertransaminasemia (AST, 1173
U/L; ALT, 1976 U/L), elevated lactated dehydrogenase
(LDH, 1066 U/L), hyperferritinemia (555 ng/ml), and
hepatosplenomegaly with multiple small iso-hypoechoic
splenic nodules (Figure 1, Pt 3). Blood cultures showed no
bacterial or fungal growth. Serological tests for herpes-
viruses, hepatitis viruses, HIV, parvovirus B19, Borrelia,
and Toxoplasma, as well as the tuberculin sensitivity test
yielded negative results. No Leishmania amastigotes were
observed in the bone marrow aspirate, while DNA specific
for Leishmania spp. and for L.infantum was detected by
real-time PCR. In addition, RapydTest and IFAT (titer:
1:160) were positive for anti-Leishmania antibodies. Treat-
ment for VL with LAMB (10 mg/kg IV) was adminis-
tered. Defervescence occurred after 4 days, whereas
levels of inflammatory and hepatic markers decreased
gradually, and Hb level returned to normal within 15 days.
Hepatosplenomegaly and nodules completely resolved
after 2 months.
Patient 4
An 18-month-old boy was admitted to the St. Orsola-
Malpighi University Hospital with FUO, hypertransamina-
semia (AST, 422; ALT, 261 U/L), elevation of inflammatory
markers (LDH, 1233 U/L; ferritin, 1750 ng/mL; sIL2R,
>7500 UI/mL), and splenomegaly with iso-hypoechoic
nodules (Figure 1, Pt 4). At first, the clinical findings were
ascribed to EBV infection because of anti-EBV IgM posi-
tivity. Nevertheless, the RapydTest was positive for anti-
Leishmania antibodies, and IFAT was weakly positive
(titer, 1:40). No parasites were detected on microscopic
examination of a bone marrow smear, while the bone mar-
row aspirate tested positive for Leishmania spp. and for L.
infantum DNA by real-time PCR. These laboratory find-
ings and the clinical data, including spleen nodularity, sug-
gested a diagnosis of VL, and the patient was treated with
LAMB (10 mg/kg IV). The fever resolved within 2 days
after treatment. Hepatosplenomegaly and spleen nodules
completely resolved after 3 months, inflammatory and
hepatic markers decreased gradually to normal levels after
4 months.
Altogether, 4 out of 4 patients were disease-free with a
mean follow-up of 18 months (16–20 months).
Conclusions
Delays in diagnosis of VL are common because of vari-
able incubation time, presence of nonspecific symptoms,
difficulty in microscopic identification of rare amasti-
gotes in bone marrow smears, and negative results on
serological tests, especially in immunosuppressed patients
or in the early stages of HLH caused by Leishmania [11].
VL is usually diagnosed by serological tests and parasite
detection, the latter including parasitological and molecu-
lar methods [12].
In our pediatric cases, microscopic examination of bone
marrow smears failed to show the presence of amasti-
gotes. This is not surprising, because the sensitivity of mi-
croscopy for detecting VL is 50–80% [12], and this value
is further reduced in HLH [11]. Nevertheless, leishmanial
DNA was detected in the bone marrow of 4 out of 4 cases,
and in 3 out of 4 cases (Patient 2, Patient 3 and Patient
4) we could confirm that VL was caused by L.infantum.
Thus, in line with published data [9], we observed that
molecular methods significantly enhanced Leishmania
detection in bone marrow samples. In addition, anti-
Leishmania antibodies were detected in all 4 cases. Thus,
molecular and serological tests as well as clinical suspicion
were crucial for VL diagnosis in our experience, and posi-
tive response to anti-Leishmania treatment indicated that
our diagnostic approach was effective. All of our patients
displayed splenomegaly with peculiar sonographic features
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of multifocal hypoechoic nodules. We believe that this
peculiar ultrasound finding, in association with clinical
and laboratoristic criteria, as fever, hepatosplenomegaly,
anemia, leucopenia and weight loss, may corroborate
the suspicion of VL that should be confirmed by sero-
logical and/or molecular tests [13].
Spleen nodules where identified in 4 out of 5 children
diagnosed with VL during the recent outbreak occurred
in Bologna Province of Italy from November 2012 to
May 2013 [4]. However spleen nodules may represent a
non specific finding, as they are reported also in several
other rare pathologic conditions in children including
type I Gaucher disease [14], granulomatous disease, bac-
terial abscess (staphylococci, streptococci, salmonella, E.
coli), fungal infection (Candida albicans), Mycobacterium
tuberculosis infection [15], or lymphoproliferative disor-
ders. Case reports of spleen nodules in VL patients have
been previously documented by CT scan or MRI [16,17],
however rarely documented in a series of cases as in our
report.
VL patients may fulfill several criteria of HLH scoring
[6,18], as in Patient 1; however detection of spleen no-
dules does not match specifically with familial HLH or
HLH secondary to viruses, with only one case reported
[19]. Intracellular parasites have an interesting propen-
sity to trigger HLH, and Leishmania is one of the most
frequently involved non-viral agent. Differential diagno-
sis between familial and secondary HLH and VL may be
difficult, since both pathologic entities may present with
nonspecific symptoms and share some laboratory diag-
nostic features, including marked elevation of inflamma-
tory markers [11,18,19].
In conclusion, increasing the number of diagnostic
tools to identify VL is crucial to enhance detection of
this difficult-to-diagnose infection. In our 4 patients,
spleen nodules associated with fever and anemia in-
duced the clinician to further investigate the possibility
of VL infection. We suggest that spleen nodules repre-
sent a possible hallmark of VL, especially in infants,
thus contributing to diagnosis of systemic L. infantum
infection in children.
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